{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EPOCH-F",
    "query": {
      "intervention": "EPOCH-F"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 198,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EPOCH-F&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T22:55:44.767Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02181478",
      "title": "Intra-Osseous Co-Transplant of UCB and hMSC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndromes",
        "Myelofibrosis",
        "Relapsed Non-Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Hodgkin Lymphoma",
        "Refractory Hodgkin Lymphoma",
        "Relapsed Chronic Lymphocytic Leukemia",
        "Refractory Chronic Lymphocytic Leukemia",
        "Lymphoid Malignancies",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "mesenchymal stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 6,
      "start_date": "2015-07-22",
      "completion_date": "2020-02-07",
      "has_results": false,
      "last_update_posted_date": "2020-12-04",
      "last_synced_at": "2026-09-03T22:55:44.767Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02181478"
    },
    {
      "nct_id": "NCT02538926",
      "title": "Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B Acute Lymphoblastic Leukemia",
        "B Lymphoblastic Lymphoma",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent B Lymphoblastic Lymphoma",
        "Recurrent T Lymphoblastic Leukemia/Lymphoma",
        "Refractory B Lymphoblastic Lymphoma",
        "Refractory T Lymphoblastic Lymphoma",
        "T Acute Lymphoblastic Leukemia",
        "T Lymphoblastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Asparaginase",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Imatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-07-01",
      "completion_date": "2021-07-30",
      "has_results": false,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-09-03T22:55:44.767Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02538926"
    },
    {
      "nct_id": "NCT05937776",
      "title": "Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Gadoterate Meglumine",
          "type": "OTHER"
        },
        {
          "name": "Contrast-enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2023-12-11",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-09-03T22:55:44.767Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05937776"
    },
    {
      "nct_id": "NCT05722262",
      "title": "Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "K-001",
          "type": "DRUG"
        },
        {
          "name": "K-877-ER",
          "type": "DRUG"
        },
        {
          "name": "CSG452",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kowa Research Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-02-24",
      "completion_date": "2023-04-05",
      "has_results": false,
      "last_update_posted_date": "2023-06-02",
      "last_synced_at": "2026-09-03T22:55:44.767Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05722262"
    },
    {
      "nct_id": "NCT02481310",
      "title": "Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Burkitt Lymphoma",
        "B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "MYC Gene Mutation",
        "Plasmablastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Ixazomib Citrate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2015-10-28",
      "completion_date": "2024-07",
      "has_results": true,
      "last_update_posted_date": "2022-02-21",
      "last_synced_at": "2026-09-03T22:55:44.767Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Medford, Massachusetts • New Brunswick, New Jersey + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Medford",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02481310"
    },
    {
      "nct_id": "NCT05127226",
      "title": "HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Angelman Syndrome"
      ],
      "interventions": [
        {
          "name": "ION582",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "0 Years to 50 Years"
      },
      "enrollment_count": 71,
      "start_date": "2021-12-22",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-09-03T22:55:44.767Z",
      "location_count": 6,
      "location_summary": "San Diego, California • Aurora, Colorado • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Carrboro",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05127226"
    },
    {
      "nct_id": "NCT06735235",
      "title": "Salivary Fluoride Clearance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Caries"
      ],
      "interventions": [
        {
          "name": "0 ppm F",
          "type": "DRUG"
        },
        {
          "name": "250 ppm F as MFP",
          "type": "DRUG"
        },
        {
          "name": "1100 ppm as MFP",
          "type": "DRUG"
        },
        {
          "name": "2800 ppm F as MFP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Procter and Gamble",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2021-07-14",
      "completion_date": "2021-07-29",
      "has_results": false,
      "last_update_posted_date": "2024-12-16",
      "last_synced_at": "2026-09-03T22:55:44.767Z",
      "location_count": 1,
      "location_summary": "Mason, Ohio",
      "locations": [
        {
          "city": "Mason",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06735235"
    },
    {
      "nct_id": "NCT03471182",
      "title": "Investigation of Cocaine Addiction Using mGluR5 PET and fMRI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine Dependence"
      ],
      "interventions": [
        {
          "name": "Psychiatric and Cognitive Testing",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Cocaine Self-adminstration",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 32,
      "start_date": "2018-02-26",
      "completion_date": "2022-08-18",
      "has_results": true,
      "last_update_posted_date": "2024-02-29",
      "last_synced_at": "2026-09-03T22:55:44.767Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03471182"
    },
    {
      "nct_id": "NCT06356610",
      "title": "Pharmacokinetic and Subjective Effects of Heated Tobacco Products",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tobacco Use"
      ],
      "interventions": [
        {
          "name": "Product A",
          "type": "OTHER"
        },
        {
          "name": "Product B",
          "type": "OTHER"
        },
        {
          "name": "Product C",
          "type": "OTHER"
        },
        {
          "name": "Product D",
          "type": "OTHER"
        },
        {
          "name": "Product E",
          "type": "OTHER"
        },
        {
          "name": "Product F",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Altria Client Services LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "22 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2024-02-06",
      "completion_date": "2024-12-18",
      "has_results": true,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-09-03T22:55:44.767Z",
      "location_count": 3,
      "location_summary": "Lexington, Kentucky • Springfield, Missouri • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06356610"
    },
    {
      "nct_id": "NCT02723630",
      "title": "Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Lenvatinib 10 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2013-07",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2019-03-14",
      "last_synced_at": "2026-09-03T22:55:44.767Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02723630"
    }
  ]
}